Newsletter Edition #335
[GHF Plus: Global Health Policy Intelligence]
This edition was first published on March 13, 2026.
Readers,
In this edition, we bring you a mapping of pharma litigation in 2025. The idea was to give a snapshot of legal flashpoints.
We hope you find this useful.
My colleague Khushi Makwana, an India-based lawyer, has put this together for our subscribers. She has been a part of our annual fellowship program.
This premium offering is for our core supporters who have expressed interest in GHF Plus, a premium offering on global health intelligence. We announced this last year and have since served up research reports and other tools every quarter. You will find previous GHF Plus products at the end of this edition when you scroll below, and in our archives.
Learn more about the various tiers of subscriptions we offer. GHF Basic is for all our paying subscribers. GHF Plus is a higher tier for our core supporters. If you want to consider upgrading to access our premium products, please drop me a line. Alternatively, one can also upgrade from an existing paid subscription to this tier.
Journalism in Geneva is tough and expensive to sustain. Reader support helps us show up, and not shut shop.
We are keen on providing value to our readership of global health experts. If you have specific ideas and projects you'd like us to work on, please let us know by simply replying to this email. We will give it our utmost consideration.
Thanks!
Priti Patnaik, Founder & Publisher, Geneva Health Files
Feel free to write to us: genevahealthfiles@gmail.com ; Find us on BlueSky, Instagram and Linkedin
Priti Patnaik
Pharmaceutical Litigation in 2025: A Global Snapshot of Legal Flashpoints
By Khushi Makwana
Julia Dötzer & Priti Patnaik contributed to this project
Makwana is a legal and healthcare management professional with a focus on healthcare policy, compliance, and systems improvement. She can be reached at officekhushimakwana@gmail.com.
In 2025, the pharmaceutical industry faced a broad wave of litigation that spanned intellectual property defence, antitrust enforcement, pricing regulation challenges, public health access disputes, and product safety claims. A detailed case tracker and accompanying world map highlight the geographic spread and thematic concentration of these conflicts, with the United States serving as the primary battleground while emerging markets contributed notable access-focused cases.
Intellectual property disputes accounted for the largest share of activity. One of the most prominent trends remains the dominance of patent and regulatory exclusivity disputes, particularly in biologics, biosimilars, and mRNA based technologies.
